Perifosine-a new option in treatment of acute myeloid leukemia?

Janusz Krawczyk, Niamh Keane, Ronan Swords, Michael O'Dwyer, Ciara L. Freeman, Francis J. Giles

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models, perifosine has an independent cytotoxic potential but also synergizes well with other rationally selected targeted agents. The evidence from clinical trials supporting the use of perifosine in the therapy of leukemias is limited. The optimal dose and schedule have yet to be defined. However, given its favorable toxicity profile and mechanism of action, the therapeutic potential of perifosine should be evaluated in well-designed clinical trials. Areas covered: The role of the phosphatidylinositol-3 kinase (PI3K)/Akt zpathway in normal cells, cancer and leukemias is discussed. The mechanism of action of perifosine and the basic information on the development and chemical properties are summarized. The evidence from in vivo and in vitro studies is presented. The efficacy and side effect profile are summarized. Expert opinion: The safety and tolerability profile of perifosine are satisfactory. The evidence from clinical trials in patients with leukemias is very limited. The preclinical data are encouraging. Perifosine has the potential to play a role in the treatment of leukemias in the future. Its role needs to be confirmed in clinical trials.

Original languageEnglish (US)
Pages (from-to)1315-1327
Number of pages13
JournalExpert Opinion on Investigational Drugs
Issue number10
StatePublished - Oct 2013
Externally publishedYes


  • Acute myeloid leukemia
  • Chronic lymphocytic
  • Leukemia
  • PI3K/AKT pathway
  • Perifosine
  • Targeted molecular therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Perifosine-a new option in treatment of acute myeloid leukemia?'. Together they form a unique fingerprint.

Cite this